Q3 2024 EPS Estimates for Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Boosted by HC Wainwright

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Research analysts at HC Wainwright lifted their Q3 2024 EPS estimates for shares of Enlivex Therapeutics in a report released on Monday, September 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.16) per share for the quarter, up from their previous forecast of ($0.18). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.14) EPS and FY2025 earnings at ($0.58) EPS.

Separately, EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th.

Enlivex Therapeutics Stock Up 21.4 %

Shares of Enlivex Therapeutics stock opened at $1.59 on Wednesday. Enlivex Therapeutics has a 12-month low of $1.15 and a 12-month high of $4.59. The firm has a market capitalization of $33.19 million, a PE ratio of -1.14 and a beta of 1.03. The stock’s fifty day moving average is $1.31 and its 200-day moving average is $1.92.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06.

Hedge Funds Weigh In On Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd bought a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned 0.12% of Enlivex Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.